Biotech Venture Funding January 2026

Private financings from January 2026 — Company, date, round, investors, therapeutic area, and a one-line "what they do." Latest VC deals here → 2026 VC Tracker Last updated: 01 Feb 2026

Breakthru Medicine Series A

Date: 29-Jan-2026 | Size: US$60M | Therapeutic area: Oncology (multi-modality platform)

Investors: Not disclosed (press release notes board/investors including Dave Morehead; Fred Eshelman (Eshelman Ventures); Mark Gergen)

What they do: Oncology company developing "disruptive therapeutic modalities" for solid tumors; platform spans small molecules, next-gen ADC payloads, and molecular glues (details of specific programs not publicly disclosed at announcement).

Tenpoint Therapeutics Series B + Credit Facility

Date: 28-Jan-2026 | Size: US$235M total (US$85M Series B + US$150M term loan) | Therapeutic area: Ophthalmology (presbyopia)

Investors: Series B led by Janus Henderson, EQT Nexus, Hillhouse, British Business Bank; existing EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille; term loan facility from Hercules Capital

What they do: Commercial biotech focused on rejuvenating vision in the aging eye; financing supports commercialization/launch of YUVEZZI (carbachol + brimonidine) for presbyopia (once-daily dual-agent eye drop).

Sensorion Public Financing / Reserved Offering

Date: 28-Jan-2026 | Size: €60M (incl. €20M strategic) | Therapeutic area: Genetic medicine (hearing loss)

Investors: Sanofi (€20M strategic); existing Redmile Group, Artal (advised by Invus), Sofinnova Partners; other investors incl. Cormorant Asset Management, Coastlands Capital, Sphera Healthcare

What they do: Clinical-stage biotech developing genetic medicines to restore/treat/prevent hearing loss; proceeds support SENS-601 (GJB2 gene therapy) advancement toward clinic and continued development of SENS-501.

TRex Bio Financing

Date: 27-Jan-2026 | Size: US$50M (oversubscribed) | Therapeutic area: Immunology / inflammation (tissue Treg biology)

Investors: New Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors; existing Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Polaris Partners, SV Health Investors

What they do: Clinical-stage biotech developing precision immunoregulatory medicines based on tissue Treg biology; proceeds support continued development of TRB-061 (TNFR2 agonist) in atopic dermatitis and advancement of preclinical programs TRB-071/TRB-081 toward the clinic.

CORXEL Series D

Date: 22-Jan-2026|Size: US$287M (up to)|Therapeutic area: Cardiometabolic (obesity / T2D)

Investors: New SR One, TCG Crossover (TCGX), RA Capital, HBM Healthcare Investments, SymBiosis, Adage, Invus, SilverArc (+ others); existing RTW Investments, Hengdian Group Capital

What they do: Clinical-stage cardiometabolic biotech advancing CX11, an oral small-molecule GLP-1 receptor agonist; proceeds support ongoing U.S. Phase 2 obesity study, planned global Phase 2 in T2D, and Phase 3 preparations (plus other cardio-metabolic programs).

Mendra Series A

Date: 22-Jan-2026|Size: US$82M|Therapeutic area: Rare disease (asset acquisition + AI-enabled development)

Investors: Co-led OrbiMed, 8VC, 5AM Ventures; participation Lux Capital, Wing VC

What they do: Builds a portfolio by acquiring underdeveloped rare disease assets and using AI across development + commercialization (e.g., patient identification, trial enrollment, global access) to shorten timelines for underserved patient populations.

ErVimmune Series A

Date: 21-Jan-2026|Size: €17M|Therapeutic area: Oncology (immuno-oncology / therapeutic cancer vaccines)

Investors: Seventure Partners; SPRIM Global Investments (plus access to non-dilutive support from Bpifrance / France 2030)

What they do: Developing off-the-shelf therapeutic cancer vaccines targeting shared HERV-derived tumor antigens; lead candidate ErVac01 is designed for "cold" tumors (e.g., triple-negative breast cancer, ovarian) with funding supporting first-in-human clinical development.

Infinitopes Seed Extension

Date: 21-Jan-2026|Size: US$35M|Therapeutic area: Oncology (cancer vaccines / immuno-oncology)

Investors: Co-led Octopus Ventures, Amplify Bio; new Macmillan Cancer Support; existing Cancer Research Horizons, Manta Ray Ventures

What they do: Clinical-stage precision cancer vaccine company advancing ITOP1 to prevent recurrence in oesophageal cancer, enabled by its antigen discovery platform.

Think Bioscience Series A

Date: 20-Jan-2026|Size: US$55M|Therapeutic area: Rare disease / small-molecule discovery

Investors: Led Regeneron Ventures, Innovation Endeavors, Janus Henderson Investors; participation T.A. Springer, CE-Ventures, MBX Capital, YK Bioventures; returning AV8 Ventures, CU Innovations, Buff Gold Ventures

What they do: Uses synthetic biology to uncover new "footholds" on hard targets for small-molecule drugging; lead program targets mutants driving Noonan syndrome.

Exciva Series B

Date: 20-Jan-2026|Size: €51M|Therapeutic area: Neuropsychiatry

Investors: Co-led EQT Life Sciences (LSP Dementia Fund), Gimv; participation Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, Andera Partners, LBBW

What they do: Clinical-stage neuropsychiatry company advancing Deraphan into Phase 2 for agitation associated with Alzheimer's disease.

Caldera Therapeutics Series A

Date: 14-Jan-2026|Size: US$112.5M|Therapeutic area: Immunology / Inflammation (IBD)

Investors: Founding Atlas Venture, LAV, venBio; A-1 led by Omega Funds; new Wellington Management, Janus Henderson Investors

What they do: Developing CLD-423, a first-in-class bispecific targeting IL-23p19 and TL1A for IBD and other inflammatory diseases.

Proxima Seed

Date: 13-Jan-2026|Size: US$80M|Therapeutic area: Platform (AI drug discovery)

Investors: DCVC; NVentures (NVIDIA); Braidwell; Roivant; AIX Ventures; Yosemite; Magnetic; Alexandria Venture Investments; Modi Ventures (+ others)

What they do: AI-native drug discovery company (rebranded from VantAI) building a data + ML stack for proximity-based medicines that modulate protein–protein interactions (molecular glues / PROTAC-superset).

Cytotheryx Series A

Date: 12-Jan-2026|Size: US$60M|Therapeutic area: Hepatology / Cell therapy

Investors: Ouroboros Family Founders Fund

What they do: Liver-focused cell therapy platform enabling scalable, functional human hepatocytes for multiple applications (e.g., bioartificial liver support and liver cell transplantation concepts).

Juvena Therapeutics Series B

Date: 12-Jan-2026|Size: US$33.5M|Therapeutic area: Regenerative medicine (neuromuscular / age-related disease)

Investors: Led Bison Ventures; participation Eli Lilly and Company, Jefferson Life Sciences; existing Mubadala Capital, Manta Ray

What they do: AI-enabled regenerative biologics company advancing JUV-161, a muscle-regenerating biologic in Phase 1 for myopathic muscle degeneration.

Kinaset Therapeutics Series B

Date: 10-Jan-2026|Size: US$103M|Therapeutic area: Respiratory / Immunology (asthma)

Investors: RA Capital; Forge Life Science Partners; EQT Life Sciences; Vivo; Schroders; Willett; Pictet; Sixty Degree; existing Atlas; 5AM; Gimv

What they do: Developing frevecitinib, an inhaled therapy for severe inflammatory respiratory disease, positioned to help non-eosinophilic asthma patients who lack good options.

Vibrant Therapeutics N/A

Date: 12-Jan-2026|Size: US$61M|Therapeutic area: Oncology

Investors: Pfizer Ventures; Apricot Capital; Bayland; HSG; Northern Light VC; First Principle Venture

What they do: Oncology biotech developing logic-gated "masked" T-cell engagers; lead VIB305 targets EGFR+ solid tumors, designed as a prodrug/activation concept.

bit.bio Series C

Date: 09-Jan-2026|Size: US$50M|Therapeutic area: Research tools / cell programming (enabling tech)

Investors: Led M&G Investments (other participants not disclosed in the PR)

What they do: Human cell programming company using opti-ox™ to produce consistent ioCells™ for drug discovery and tox, supporting NAMs and AI dataset generation.

MEDIPOST N/A

Date: 09-Jan-2026|Size: US$140M|Therapeutic area: Regenerative medicine / Ortho (knee OA)

Investors: Skylake Equity Partners; Crescendo Equity Partners (+ "Korea's leading growth equity fund")

What they do: Developing allogeneic umbilical cord blood–derived MSC therapies for inflammation-driven degenerative disease; funds support Phase III planning for knee osteoarthritis/cartilage defects.

AirNexis Therapeutics Series A

Date: 09-Jan-2026|Size: US$200M|Therapeutic area: Respiratory (COPD)

Investors: Led Frazier Life Sciences; participation OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital, Enavate Sciences

What they do: Developing AN01 (HSK39004), an inhaled dual PDE3/4 inhibitor in Phase 2 for COPD, in-licensed ex-China from Haisco.

Orca Bio Series F

Date: 09-Jan-2026|Size: US$250M|Therapeutic area: Oncology / cell therapy (hematologic malignancies)

Investors: Lightspeed Venture Partners (Series F lead; other participants not disclosed in the PR)

What they do: Late-stage "high-precision" allogeneic T-cell therapy company preparing for potential commercialization of Orca-T ahead of an April 2026 PDUFA date.

Parabilis Medicines Series F

Date: 08-Jan-2026|Size: US$305M|Therapeutic area: Oncology

Investors: RA Capital; Fidelity; Janus Henderson; new Frazier; Soleus (+ others); existing venBio; Cormorant; ARCH; GV; General Catalyst; Foresite; Samsara; Catalio (+ others)

What they do: Uses the Helicon™ peptide platform to drug historically "undruggable" targets in cancer; financing supports FOG-001 (zolucatetide) clinical development across tumors.

Alveus Therapeutics Series A

Date: 08-Jan-2026|Size: US$160M|Therapeutic area: Metabolic / Obesity

Investors: New Rhein Healthcare Investors; Andera Partners; Omega Funds; Sanofi Capital; Kurma Partners; Avego BioScience Capital (+ others)

What they do: Obesity/metabolic company advancing ALV-100 (bifunctional GIPR antagonist / GLP-1R agonist) plus an amylin-focused pipeline aimed at durable weight management/maintenance.

Diagonal Therapeutics Series B

Date: 08-Jan-2026|Size: US$125M|Therapeutic area: Rare disease (genetic / vascular)

Investors: Sanofi Ventures; Janus Henderson; new Deep Track; EcoR1; Logos; Balyasny; Woodline; existing Atlas; BVF; Lightspeed; RA Capital; Frazier; Viking; RV Invest; Velosity (+ others)

What they do: Developing "clustering antibodies" to correct dysregulated receptor signaling in severe genetic diseases; lead DIAG723 targets HHT and PAH.

EpiBiologics Series B

Date: 08-Jan-2026|Size: US$107M|Therapeutic area: Oncology + Immunology

Investors: GV; Johnson & Johnson (JJDC); NVF; Aulis; Avego BioScience Capital; Samsara; existing Polaris; Digitalis; Taiho Ventures; Vivo; Codon; Mission BioCapital

What they do: Builds EpiTAC: modular bispecific antibody degraders targeting extracellular membrane/soluble proteins; lead EPI-326 is an EGFR degrader headed to first-in-human.

Beacon Therapeutics Series C

Date: 08-Jan-2026|Size: Over US$75M|Therapeutic area: Ophthalmology (gene therapy)

Investors: Life Sciences at Goldman Sachs Alternatives; Retinal Degeneration Fund; existing Syncona; Forbion; Oxford Science Enterprises; Advent Life Sciences

What they do: Ocular gene therapy company advancing laru-zova for X-linked retinitis pigmentosa (XLRP) and building additional retina pipeline programs.

Mediar Therapeutics Series B

Date: 07-Jan-2026|Size: $76M|Therapeutic area: Fibrosis

Investors: Co-led Amplitude Ventures, ICG; new Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Real Estate Trust (ARE); plus existing Series A investors

What they do: Clinical-stage fibrosis company developing first-in-class therapies designed to halt fibrosis; advancing MTX-474 (EphrinB2 antagonist) in Phase 2a systemic sclerosis and MTX-439 (SMOC2 antagonist) toward Phase 1 for CKD-associated fibrosis (with an IPF program partnered).

Nocion Therapeutics Series B Extension

Date: 07-Jan-2026|Size: US$23M extension (US$93M total Series B)|Therapeutic area: Respiratory / Chronic cough

Investors: Led by Arkin Bio Capital, Monograph Capital; participation BioInnovation Capital, Canaan Partners, F-Prime Capital, Lumira Ventures, Mass General Brigham Ventures, Mission BioCapital, Morningside, Osage University Partners, and an undisclosed strategic investor

What they do: Developing taplucainium (dry powder inhalation), a locally delivered charged sodium channel blocker designed to selectively silence activated airway nociceptors with minimal systemic exposure; Phase 2b readout expected mid-2026.

Soley Therapeutics Series C

Date: 07-Jan-2026|Size: US$200M|Therapeutic area: Oncology (platform)

Investors: Surveyor Capital (primary); HRTG Partners; RWN Management; existing incl. Doug Leone Family Fund; Breyer Capital; GordonMD Global Investments (+ others)

What they do: Drug discovery company using cell stress sensing (imaging + automation + AI) to build first-in-class programs; proceeds push oncology assets (incl. AML) toward IND/clinic.

Rakuten Medical Series F

Date: 07-Jan-2026|Size: US$100M|Therapeutic area: Oncology

Investors: TaiAx (lead); Daiwa Securities; Mitsui Sumitomo Insurance; Sumitomo Mitsui Banking; ABIES Capital; Nexus CVC; OEP Group; SBI Group; Rakuten Group; Mickey Mikitani

What they do: Developing photoimmunotherapy via the Alluminox® platform (drug conjugate + targeted light activation using a device) to kill tumor cells locally.

Poplar Therapeutics Series A

Date: 07-Jan-2026|Size: US$50M|Therapeutic area: Immunology / Allergy

Investors: SR One; Vida Ventures; Platanus

What they do: Clinical-stage immunology company developing a next-gen IgE depleter (PHB-050) aimed at food allergy and other atopic diseases, with a Phase 1 underway.

Corsera Health Series A

Date: 07-Jan-2026|Size: US$80M|Therapeutic area: Cardiovascular

Investors: Forbion; Population Health Partners (+ John Maraganore)

What they do: Cardiovascular prevention company advancing COR-1004 (PCSK9 siRNA) alongside a broader prediction/prevention approach to reduce ASCVD risk.